MIA SH3 domain ER export factor 3Genealiases: D320 · ODCD2 · TANGO · TANGO1 · UNQ6077
Q-omics provides the consensus-scored MIA3 profile across patient tissues and cancer cell-line models. MIA3 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, MIA3 is differentially expressed in 12, with the highest sampling consensus in KIRC. Additionally, MIA3 RNA expression shows 21,101 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight ACC, KIRC, and UVM as cancer lineages where MIA3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MIA3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MIA3 survival associations across molecular data types. MIA3 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (7) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MIA3 RNA expression–survival associations across cancer types. High MIA3 expression shows unfavorable associations in ACC, KIRP, KICH and LGG, but favorable associations in KIRC and BRCA. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for MIA3 RNA expression.
This table summarizes MIA3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 5. The strongest signals are observed in KIRC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for MIA3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MIA3 shows lower tumor expression in THCA and KICH and higher tumor expression in KIRC, HNSC, BRCA and LIHC. The KIRC box plot shows higher MIA3 RNA expression in tumor versus normal tissue (log2 FC = +0.343, t-test p < 0.001).
This table shows molecular features associated with MIA3 in patient tissues and cancer cell lines. In patient samples, MIA3 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, MIA3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in KIDNEY, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and BLOOD_Lymphoma.
